{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(9)"],"submitter":["Antherieu G"],"pubmed_abstract":["Recently, a new subset of acute myeloid leukemia (AML) presenting a direct partial tandem duplication (PTD) of the KMT2A gene was described. The consequences of this alteration in terms of outcome and response to treatment remain unclear. We analyzed retrospectively a cohort of KMT2A-PTD-mutated patients with newly diagnosed AML. With a median follow-up of 3.6 years, the median overall survival was 12.1 months. KMT2A-PTD-mutated patients were highly enriched in mutations affecting epigenetic actors and the RTK/RAS signaling pathway. Integrating KMT2A-PTD in ELN classification abrogates its predictive value on survival suggesting that this mutation may overcome other genomic marker effects. In patients receiving intensive chemotherapy, hematopoietic stem cell transplantation (HSCT) signific"],"journal":["Cancers"],"pagination":["2272"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8126020"],"repository":["biostudies-literature"],"pubmed_title":["Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication."],"pmcid":["PMC8126020"],"pubmed_authors":["Huet S","Pigneux A","Antherieu G","Heiblig M","Bidet A","Hayette S","Migeon M","Sujobert P","Boureau L","Thomas X","Ghesquieres H"],"additional_accession":[]},"is_claimable":false,"name":"Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.","description":"Recently, a new subset of acute myeloid leukemia (AML) presenting a direct partial tandem duplication (PTD) of the KMT2A gene was described. The consequences of this alteration in terms of outcome and response to treatment remain unclear. We analyzed retrospectively a cohort of KMT2A-PTD-mutated patients with newly diagnosed AML. With a median follow-up of 3.6 years, the median overall survival was 12.1 months. KMT2A-PTD-mutated patients were highly enriched in mutations affecting epigenetic actors and the RTK/RAS signaling pathway. Integrating KMT2A-PTD in ELN classification abrogates its predictive value on survival suggesting that this mutation may overcome other genomic marker effects. In patients receiving intensive chemotherapy, hematopoietic stem cell transplantation (HSCT) signific","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-05T14:56:07.705Z","creation":"2022-02-10T13:32:52.184Z"},"accession":"S-EPMC8126020","cross_references":{"pubmed":["34068470"],"doi":["10.3390/cancers13092272"]}}